Is cancer incidence modified by SGLT2 inhibitors?
One of the most important achievements of diabetology in the second decade of the 21st century is undoubtedly the introduction of sodium-glucose cotransporter (SGLT2) inhibitors into clinical practice as a new class of glucose-lowering agents for type 2 diabetes. In addition to the glucosuria induce...
Saved in:
Main Author: | Lev M. Berstein |
---|---|
Format: | article |
Language: | EN RU |
Published: |
Endocrinology Research Centre
2019
|
Subjects: | |
Online Access: | https://doaj.org/article/e2a9284c7a5f48c585b794a470d53010 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Empagliflozin: a new strategy for nephroprotection in diabetes
by: Anton Ivanovich Korbut, et al.
Published: (2017) -
Intensification of glucose-lowering treatment in patients with diabetes mellitus type 2 on insulin therapy: Perspectives of dapagliflozin
by: Olga Yuryevna Sukhareva, et al.
Published: (2016) -
ACE inhibitors as a risk factor for hypoglycemia
by: Andrey Alexeevich Aleksandrov, et al.
Published: (2011) -
Diabetes mellitus associated with the mutation of the ABCC8 gene (MODY 12): features of clinical course and therapy
by: Alla K. Ovsyannikova, et al.
Published: (2019) -
35th Annual Conference of International Society for the Study of Diabetes in Children and Adolescents (ISPAD), 2-5 September 2009, Lyublyana
by: Ekaterina Andreevna Andrianova
Published: (2009)